Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors

Acta Oncologica

Volumn 50, Issue 7, 2011, Pages 1135-1136

  Roca, Sophie ^a   Quivy, Amandine ^a   Gross Goupil, Marine ^a   Bernhard, Jean Christophe ^b   De Clermont, Henri ^b   Ravaud, Alain ^a,c,d  

^a HÔPITAL SAINT ANDRÉ   (France)

^b HÔPITAL PELLEGRIN   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d Centre of Clinical Investigation Clinical Epidemiology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOVITINIB; EVEROLIMUS; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIANGIOGENIC THERAPY; CANCER GROWTH; CASE REPORT; CLEAR CELL CARCINOMA; COMPETITIVE INHIBITION; DRUG EFFICACY; HUMAN; KIDNEY CARCINOMA; LETTER; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; METASTATIC RENAL CELL CARCINOMA; NEPHRECTOMY; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES; QUINOLONES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 80052873218     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.592149     Document Type: Letter

References (6)

1. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. RECORD-1 Study Group: Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010;116:4256-65.
2. Ravaud A, Digue L, Truffl andier N, Smith D. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma. Ann Oncol 2010;21: 431-2.
3. Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, et al. Sunitinib rechallenge in metas tatic renal cell carcinoma patients. Cancer 2010;116:5400-6.
4. Gr ü nwald V, Seidel C, Fenner M, Heuser M, Ganser A. Antitumor activity of tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC). Proc ASCO GU 2010; abstr 414.
5. Bracarda S, Ravaud A, Chioidi M. Mammalian target of rapamycin inhibitors in clinical practice: Case reports of everolimus in renal cell carcinoma. Eur Urol 2009;8:815-9.
6. Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 2011;16:32-44.